Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$2.1b

Trevi Therapeutics Management

Management criteria checks 3/4

Trevi Therapeutics' CEO is Jennifer Good, appointed in Mar 2011, has a tenure of 15.08 years. total yearly compensation is $2.59M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $3.54M. The average tenure of the management team and the board of directors is 5 years and 9 years respectively.

Key information

Jennifer Good

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage23.48%
CEO tenure15.1yrs
CEO ownership0.2%
Management average tenure5yrs
Board average tenure9yrs

Recent management updates

Recent updates

Trevi Therapeutics: Late-Stage Transition Meets Execution Risk

Apr 17

Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential

Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?

Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential

Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Apr 02
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Trevi adds 19% on full data set from mid-stage cough study

Sep 19

Trevi Therapeutics: Moving Forward

Sep 11

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

CEO Compensation Analysis

How has Jennifer Good's remuneration changed compared to Trevi Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$43m

Sep 30 2025n/an/a

-US$46m

Jun 30 2025n/an/a

-US$47m

Mar 31 2025n/an/a

-US$47m

Dec 31 2024US$3mUS$608k

-US$48m

Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$2mUS$597k

-US$29m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$898kUS$523k

-US$29m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$2mUS$506k

-US$34m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$478k

-US$33m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$3mUS$435k

-US$27m

Compensation vs Market: Jennifer's total compensation ($USD2.59M) is below average for companies of similar size in the US market ($USD5.29M).

Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.

CEO

Jennifer Good (60 yo)

15.1yrs
Tenure
US$2,589,035
Compensation

Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011 and had been its Interim Principal Financial Officer since Au...

Leadership Team

NamePositionTenureCompensationOwnership
Jennifer Good
Co-Founder15.1yrsUS$2.59m0.17%
$ 3.5m
James Cassella
Chief Development Officer1.6yrsUS$1.90m0%
$ 0
Thomas Sciascia
Co-Founder & Chief Scientific Officer15.1yrsUS$977.13k0.17%
$ 3.7m
David Hastings
Chief Financial Officer & Principal Financial Officerless than a yearno datano data
Christopher Galletta
Controller & Chief Accounting Officer5yrsno data0.020%
$ 433.2k
Katie McManus
Communications Managerno datano datano data
Farrell Simon
Chief Commercial Officer5.6yrsno data0.063%
$ 1.4m
Katherine Takaki
Senior VP of Global Regulatory Affairs1.3yrsno datano data
5.0yrs
Average Tenure
64yo
Average Age

Experienced Management: TRVI's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jennifer Good
Co-Founder15.1yrsUS$2.59m0.17%
$ 3.5m
Anne VanLent
Independent Director7.5yrsUS$133.25k0.020%
$ 431.5k
Dominick Colangelo
Independent Director5.8yrsUS$125.75k0%
$ 0
Edward Mathers
Independent Director8.8yrsUS$115.75k0%
$ 0
David Meeker
Independent Chairman of the Board8.8yrsUS$143.25k0.27%
$ 5.9m
Michael Heffernan
Independent Director9.2yrsUS$133.25k0.0049%
$ 105.5k
Jeffrey Bernhard
Member of Clinical Advisory Board13.1yrsno datano data
Dawn McGuire
Member of Clinical Advisory Board13.1yrsno datano data
9.0yrs
Average Tenure
63yo
Average Age

Experienced Board: TRVI's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 17:02
End of Day Share Price 2026/04/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Trevi Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
William WoodB. Riley Securities, Inc.